Alabama Pharmacy Board Defense Lawyer – Call Today – FDA Looking to Approve Lixisenatide Type 2 Diabetes Drug – (866) 348-2889
The FDA is considering approval for Sanofi’s lixisenatide type 2 diabetes treatment.
Lixisenatide is a once-daily prandial glucagon-like peptide-1 (GLP-1) receptor agonist. The brand name in the United States is still under consideration, but it approved as Lyxumia in Europe and other countries.
Sanofi originally submitted a New Drug Application (NDA) for lixisenatide in 2013, but the company pulled that application because the FDA was concerned about the cardiovascular safety of similar diabetes drugs.
Alabama Pharmacist Defense Lawyer, Alabama Defense Lawyer, Board of Pharmacy, Pharmacy Defense Attorney